Related Experiment Videos
Dexamethasone therapy for children with bacterial meningitis. Meningitis Study Group
E R Wald1, S L Kaplan, E O Mason
1University of Pittsburgh School of Medicine, Pennsylvania, USA.
Pediatrics
|January 1, 1995
Summary
Dexamethasone did not significantly improve outcomes for children with bacterial meningitis. The study found no difference in hearing loss or neurologic sequelae between those receiving dexamethasone and those receiving a placebo.
Area of Science:
- Pediatric Infectious Diseases
- Neurology
- Audiology
Background:
- Bacterial meningitis is a serious infection in children that can lead to long-term complications.
- Sensorineural hearing loss and neurologic sequelae are common adverse outcomes.
- Corticosteroids like dexamethasone are sometimes used to reduce inflammation and potential complications.
Purpose of the Study:
- To evaluate the efficacy of dexamethasone in reducing sensorineural hearing loss and neurologic sequelae in children with bacterial meningitis.
- To compare outcomes in children treated with ceftriaxone plus dexamethasone versus ceftriaxone alone.
Main Methods:
- A prospective, multicentered, placebo-controlled clinical trial involving 143 children (8 weeks to 12 years) with bacterial meningitis.
- Participants received ceftriaxone with or without dexamethasone for 4 days.
- Auditory brainstem responses, hearing, development, and neurologic outcomes were assessed at multiple time points up to 1 year.
Main Results:
- No significant difference in auditory outcomes was observed between the dexamethasone and placebo groups.
- Twenty-two children initially presented with bilateral moderate to severe hearing loss; hearing impairment resolution was similar in both groups.
- No differences in neurologic or developmental outcomes were found between the treatment groups.
Conclusions:
- Dexamethasone treatment did not significantly improve audiologic, neurologic, or developmental outcomes in children with bacterial meningitis.
- Persistent hearing loss was evident early, often at the time of initial auditory brainstem response testing.